Top entities: Biohaven Pharmaceutical Holding Company, Levi & Korsinsky, Joseph E. Levi.

What category does this event fall under?

Regulatory — classified as class action lawsuit.

What is the sentiment of coverage?

Aggregate sentiment score: -50 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Regulatory class action lawsuit

Biohaven Class Action Securities Lawsuit

Q: When did this event occur?

First reported Jul 25, 2025; last updated Aug 11, 2025.

Q: What is the market impact?

General. The market is negatively impacted by the class action lawsuit against Biohaven Pharmaceutical Holding Company, as it suggests potential financial liabilities and a loss of investor confidence due to alleged securities fraud.

Analysis based on 11 articles · First reported Jul 25, 2025 · Last updated Aug 11, 2025

Sentiment

-50

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The market is negatively impacted by the class action lawsuit against Biohaven Pharmaceutical Holding Company, as it suggests potential financial liabilities and a loss of investor confidence due to alleged securities fraud. This could lead to a decrease in Biohaven Pharmaceutical Holding Company's stock price and a cautious outlook for similar biotechnology companies.

Pharmaceuticals Biotechnology

Event Summary

Levi & Korsinsky has initiated a class action securities lawsuit against Biohaven Pharmaceutical Holding Company, notifying investors of alleged securities fraud between March 24, 2023, and May 14, 2025. The lawsuit claims that Biohaven Pharmaceutical Holding Company made false statements and concealed information regarding the regulatory prospects and efficacy of its product candidates, troriluzole (for SCA) and BHV-7000 (for bipolar disorder). These alleged misrepresentations are believed to have had a significant negative impact on Biohaven Pharmaceutical Holding Company's business and financial condition. Investors who suffered losses during the specified period have until September 12, 2025, to request to be appointed as lead plaintiff.

Entities Involved

stock

Biohaven Pharmaceutical Holding Company

Biohaven Pharmaceutical Holding Company is the target of a class action lawsuit due to alleged false statements and concealment regarding its product candidates, troriluzole and BHV-7000, which negatively impacted its business and financial condition.

Importance 100.0 Sentiment -70.0

priv

Levi & Korsinsky

Levi & Korsinsky is the law firm initiating and representing investors in the class action securities lawsuit against Biohaven Pharmaceutical Holding Company.

Importance 80.0 Sentiment 50.0

per

Joseph E. Levi

Joseph E. Levi is an attorney at Levi & Korsinsky, involved in notifying investors about the class action lawsuit against Biohaven Pharmaceutical Holding Company.

Importance 30.0 Sentiment 40.0

Relationships

Levi & Korsinsky related ↔ Joseph E. Levi

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard